Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Jay Brandes who wrote (745)	6/30/1998 9:42:00 PM
From: JF Quinnelly	Respond to of 1728

"Now Motorola and Packard will contribute a total of $19 million over the next five years to develop instrumentation and mass-production techniques for the technology. In return, Motorola and Packard will get the licensing rights to the 19 inventions that Argonne developed in conjunction with the research. The market could be big, but the path to profits is not totally clear. One major competitor in the biochip arena, California-based Affymetrix Inc., said that the the technology the Argonne group claims to have pioneered may in fact infringe on Affymetrix patents. Affymetrix's senior vice president and general counsel, Vern Norviel, said his company has 14 patents that have been granted but not yet published. So, he said, he finds it hard to believe the Argonne group knows for certain that its process is a breakthrough. Istavan said there are major differences between his group's biochip and Affymetrix's. The new chip, he said, analyzes longer strands of genetic material and can do so in three dimensions."